Equillium Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Die Gewinne von Equillium werden voraussichtlich zurückgehen um 27.6% pro Jahr. Der Gewinn je Aktie wird voraussichtlich um 10.7% pro Jahr sinken.

Wichtige Informationen

-27.6%

Wachstumsrate der Gewinne

-10.74%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	25.2%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	15 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Analyseartikel • Nov 10

Investors Don't See Light At End Of Equillium, Inc.'s (NASDAQ:EQ) Tunnel

Equillium, Inc.'s ( NASDAQ:EQ ) price-to-sales (or "P/S") ratio of 4x might make it look like a strong buy right now...

Analyseartikel • Jul 18

Equillium, Inc.'s (NASDAQ:EQ) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Those holding Equillium, Inc. ( NASDAQ:EQ ) shares would be relieved that the share price has rebounded 28% in the last...

Analyseartikel • Mar 31

Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive

Equillium, Inc. ( NASDAQ:EQ ) shareholders that were waiting for something to happen have been dealt a blow with a 47...

Analyseartikel • Feb 12

Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Equillium, Inc. ( NASDAQ:EQ ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...

Analyseartikel • Nov 16

Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge

Equillium, Inc. ( NASDAQ:EQ ) shareholders won't be pleased to see that the share price has had a very rough month...

Analyseartikel • Sep 26

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

A week ago, Equillium, Inc. ( NASDAQ:EQ ) came out with a strong set of quarterly numbers that could potentially lead...

Analyseartikel • May 03

Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Equillium, Inc. ( NASDAQ:EQ ) shareholders will have a reason to smile today, with the analysts making substantial...

Analyseartikel • Mar 26

Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Seeking Alpha • Aug 15

Equillium GAAP EPS of -$0.41 in-line

Equillium press release (NASDAQ:EQ): Q2 GAAP EPS of -$0.41 in-line. Cash, cash equivalents and short-term investments totaled $57.6 million as of June 30, 2022, compared to $68.8 million as of March 31, 2022.

Seeking Alpha • Oct 08

Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)

Equillium is a clinical-stage biotech company treating severe autoimmune and inflammatory disorders. CEO Bruce Steel discusses primary drug itolizumab pivotal study. Alternative to short-term, high dose steroid therapies.

Analyseartikel • Mar 09

Is Equillium, Inc.'s (NASDAQ:EQ) Shareholder Ownership Skewed Towards Insiders?

Every investor in Equillium, Inc. ( NASDAQ:EQ ) should be aware of the most powerful shareholder groups. Large...

Analyseartikel • Nov 24

How Much Of Equillium, Inc. (NASDAQ:EQ) Do Insiders Own?

A look at the shareholders of Equillium, Inc. (NASDAQ:EQ) can tell us which group is most powerful. Institutions often...

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:EQ - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2028	N/A	-50	-50	-45	6
12/31/2027	N/A	-36	-39	-35	7
12/31/2026	N/A	-27	-24	-23	7
3/31/2026	N/A	-19	-19	-19	N/A
12/31/2025	N/A	-22	-23	-23	N/A
9/30/2025	4	-24	-23	-23	N/A
6/30/2025	17	-20	-22	-22	N/A
3/31/2025	30	-14	-18	-18	N/A
12/31/2024	41	-8	-19	-19	N/A
9/30/2024	46	-5	-22	-21	N/A
6/30/2024	43	-8	-16	-16	N/A
3/31/2024	38	-12	-23	-23	N/A
12/31/2023	36	-13	-22	-22	N/A
9/30/2023	43	-8	12	12	N/A
6/30/2023	34	-18	0	0	N/A
3/31/2023	25	-29	-5	-5	N/A
12/31/2022	16	-62	-9	-9	N/A
9/30/2022	N/A	-76	-47	-47	N/A
6/30/2022	N/A	-72	-41	-41	N/A
3/31/2022	N/A	-67	-37	-36	N/A
12/31/2021	N/A	-39	-32	-32	N/A
9/30/2021	N/A	-37	-30	-30	N/A
6/30/2021	N/A	-34	-28	-28	N/A
3/31/2021	N/A	-31	-26	-26	N/A
12/31/2020	N/A	-30	-25	-25	N/A
9/30/2020	N/A	-28	-26	-25	N/A
6/30/2020	N/A	-28	-25	-25	N/A
3/31/2020	N/A	-27	-25	-25	N/A
12/31/2019	N/A	-26	N/A	-23	N/A
9/30/2019	N/A	-23	N/A	-18	N/A
6/30/2019	N/A	-22	N/A	-15	N/A
3/31/2019	N/A	-18	N/A	-11	N/A
12/31/2018	N/A	-13	N/A	-8	N/A
9/30/2018	N/A	-10	N/A	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: EQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: EQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: EQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von EQ schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: EQ wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von EQ in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/05/18 10:46
Aktienkurs zum Tagesende	2026/05/18 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Equillium, Inc. wird von 13 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
William Wood	B. Riley Securities, Inc.
Steven Seedhouse	Cantor Fitzgerald & Co.
Roger Song	Jefferies LLC

Equillium Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 232%

Price target decreased by 49% to US$3.33

Consensus revenue estimates fall by 27%

Consensus revenue estimates increase by 35%

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Recent updates

Equillium, Inc., Annual General Meeting, May 28, 2026

New major risk - Revenue size

Equillium, Inc. announced that it has received $34.99823 million in funding from RA Capital Management, L.P.

Senior VP & COO notifies of intention to sell stock

Senior VP & COO notifies of intention to sell stock

Senior VP & COO notifies of intention to sell stock

Third quarter 2025 earnings released: US$0.065 loss per share (vs US$0 in 3Q 2024)

Equillium, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Investors Don't See Light At End Of Equillium, Inc.'s (NASDAQ:EQ) Tunnel

Equillium, Inc. Announces Management Changes , Effective October 1, 2025

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

First half 2025 earnings released: US$0.40 loss per share (vs US$0.064 loss in 1H 2024)

Equillium, Inc. announced that it expects to receive $49.996917 million in funding from a group of investors

New major risk - Share price stability

Equillium, Inc.'s (NASDAQ:EQ) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

New major risk - Share price stability

Nasdaq Grants Equillium an Additional 180 Calendar Days, Until December 8, 2025, to Regain Compliance with the Minimum Bid Price Requirement

First quarter 2025 earnings released: US$0.24 loss per share (vs US$0.078 loss in 1Q 2024)

Equillium, Inc. Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive

Equillium, Inc., Annual General Meeting, May 21, 2025

New major risk - Share price stability

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Consensus EPS estimates fall by 232%

Equillium and Biocon Limited Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

High number of new directors

Equillium, Inc. Announces Board and Committee Changes

Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge

New major risk - Financial position

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.11 loss in 3Q 2023)

Price target decreased by 49% to US$3.33

Consensus revenue estimates fall by 27%

Lacklustre Performance Is Driving Equillium, Inc.'s (NASDAQ:EQ) 28% Price Drop

Consensus revenue estimates increase by 35%

Forecast to breakeven in 2024

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Financial position

New major risk - Share price stability

Equillium, Inc. Announces Positive Interim Analysis from Phase 3 Equator Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Benign Growth For Equillium, Inc. (NASDAQ:EQ) Underpins Stock's 54% Plummet

Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101

Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

New minor risk - Profitability

Forecast to breakeven in 2024

First quarter 2024 earnings released: US$0.078 loss per share (vs US$0.11 loss in 1Q 2023)

We Think Equillium (NASDAQ:EQ) Needs To Drive Business Growth Carefully

Price target increased by 9.5% to US$6.75

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis

Consensus EPS estimates fall by 188%

Little Excitement Around Equillium, Inc.'s (NASDAQ:EQ) Revenues

New major risk - Share price stability

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

New minor risk - Share price stability

Price target decreased by 10% to US$6.17

Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

New minor risk - Shareholder dilution

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Analyst Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.

Consensus revenue estimates increase by 187%